10-Q: Oncotelic Therapeutics Reports First Quarter 2025 Results

Oncotelic Therapeutics files its Form 10-Q for the quarter ended March 31, 2025, detailing its financial results and business activities.

Summary

• Oncotelic Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025.
• The company is developing OT-101 through a joint venture with Dragon Overseas Capital Limited and GMP Biotechnology Limited for various cancers and COVID-19.
• The company is also developing Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing.
• The company incurred a net loss of $364,264 for the quarter ended March 31, 2025, compared to a net loss of $475,175 for the same period in 2024.
• Research and development expenses were $297 for the quarter ended March 31, 2025, compared to $480 for the same period in 2024.
• General and administrative expenses were $100,803 for the quarter ended March 31, 2025, compared to $166,742 for the same period in 2024.
• The company had cash of $79,173 as of March 31, 2025, compared to $86,128 as of December 31, 2024.
• The company has a negative working capital of approximately $19.4 million as of March 31, 2025.
• The company obtained short term loans of approximately $0.15 million from Autotelic Inc., a related party, during the three months ended March 31, 2025.
• The company obtained a short-term loan of $10 thousand from Amit Shah, its CFO, during three months ended March 31, 2025.
• The company's long-term plans include continued development of its current pipeline of products and generating sufficient revenues or raising additional financing to cover its anticipated expenses.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the company's ongoing losses, negative working capital, and going concern uncertainty, although there are some positive developments such as the decrease in net loss and the progress in clinical trials.

Positives

• The net loss decreased from $475,175 in Q1 2024 to $364,264 in Q1 2025.
• Research and development expenses decreased from $480 in Q1 2024 to $297 in Q1 2025.
• General and administrative expenses decreased from $166,742 in Q1 2024 to $100,803 in Q1 2025.
• The company successfully completed a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors.

Negatives

• The company has a negative working capital of approximately $19.4 million as of March 31, 2025.
• The company has incurred net accumulated losses of approximately $38.3 million since inception of Oncotelic Inc.
• The company has negative cash flows from operations for the three months ended March 31, 2025 of approximately $ 0.2 million.

Risks

• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company has a significant amount of debt, including convertible debentures and short-term debt.
• The company's success depends on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.
• The company may not be able to obtain additional financing on acceptable terms or at all.
• The company's ability to use net operating loss carryforwards may be subject to annual limitations.

Future Outlook

The company plans to continue developing its current pipeline of products, generate sufficient revenues, or raise additional financing to cover its anticipated expenses. GMP Bio is progressing with its strategic and operational plans, which include efforts to secure third-party financing and a possible initial public offering in Hong Kong during 2026.

Management Comments

• Management expects to incur significantly lower costs and losses in the foreseeable future, as a majority of the costs related with the development of OT-101 will be incurred by the JV.
• Management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern.

Industry Context

The company operates in the biopharmaceutical industry, which is characterized by high levels of risk and uncertainty. The success of the company depends on its ability to develop and commercialize new drugs, which is a lengthy and expensive process.

Comparison to Industry Standards

• It is difficult to compare Oncotelic's results directly to industry standards due to its unique business model and stage of development.
• Many comparable companies are larger, have more diversified product portfolios, and have greater access to capital.
• For example, companies like Amgen, Gilead Sciences, and Biogen have significantly larger revenues and market capitalizations.
• However, Oncotelic's joint venture with GMP Bio and its focus on developing novel immunotherapies could provide a competitive advantage in the long term.
• The company's ability to secure additional financing and advance its product candidates through clinical trials will be critical to its success.

Legal Proceedings

• One of the company's ex-employees has made a breach of employment contract claim against the company.
• The company and its legal counsel are evaluating the validity of the claim and are hopeful to attain a positive outcome.

Related Party Transactions

• The company obtained short term loans of approximately $0.15 million from Autotelic Inc., a related party, during the three months ended March 31, 2025.
• The company obtained a short-term loan of $10 thousand from Amit Shah, its CFO, during three months ended March 31, 2025.
• In April 2019, the Company issued a convertible note to Dr. Trieu totaling $ 164,444 , including OID of $ 16,444 , receiving net proceeds of $ 148,000 , which was used by the Company for working capital and general corporate purposes.
• The Company issued a Fall 2019 Note to Dr. Trieu in the principal amount of $ 250,000 .
• Dr. Trieu also offset certain amounts due to him in the amount of $ 35,000 and was converted into the Fall 2019 debt.
• During the year ended December 31, 2020, Dr. Trieu purchased a total of 5 Units under the private placement for a gross total of $ 250,000 .
• During the year ended December 31, 2023, Dr Trieu provided short term loan of $ 50 thousand to the Company.
• The balance due and payable to Dr. Trieu, as of March 31, 2025 and 2024, respectively, was $ 50,000 .
• As of January 1, 2024, approximately $ 1.5 million was outstanding and payable to Autotelic.
• During the year ended December 31, 2024 Autotelic Inc. provided additional short-term funding of approximately $ 0.6 million to the Company.
• In the three months ended March 31, 2025 Autotelic Inc. provided additional short-term funding of $ 150,000 to the Company.
• As such, approximately $ 2.2 million was outstanding and payable to Autotelic at March 31, 2025.
• As of January 1, 2024, approximately $ 35,000 was outstanding and payable to the Companys CFO.
• During the year ended December 31, 2024, the CFO provided additional short-term funding of $ 41,000 .
• In the three months ended March 31, 2025, the CFO provided additional short-term funding of $ 10,000 to the Company.
• As such, approximately $ 86,000 was outstanding and payable to the Companys CFO at March 31, 2025.
• In December 2023, the Company received $ 50,000 from the Companys CEO.
• As such, $ 50,000 was outstanding to the Companys CEO at March 31, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial condition and potential need to curtail operations.
• Customers and partners may be impacted by the company's ability to continue developing and commercializing its products.
• Creditors face the risk of non-payment due to the company's limited capital resources.

Next Steps

• The company plans to continue developing its current pipeline of products.
• The company plans to generate sufficient revenues or raise additional financing to cover its anticipated expenses.
• GMP Bio is progressing with its strategic and operational plans, which include efforts to secure third-party financing and a possible initial public offering in Hong Kong during 2026.
• The company plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers.

Key Dates

Keywords

OT-101, GMP Bio, Joint Venture, Convertible Notes, Clinical Trials, Research and Development, Oncotelic Therapeutics, Financial Results, COVID-19, Cancer